A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour

Acta Oncologica

Volumn 35, Issue 8, 1996, Pages 989-994

  Wood, Pauline J ^a   Horsman, Michael R ^b   Khalil, Azza A ^b   Steinberg, Fritz ^c   Streffer, Christian ^c   Overgaard, Jens ^b   Stratford, Ian J ^a   Adams, Gerald E ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL;

ANIMAL EXPERIMENT; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; GLUCOSE METABOLISM; HYPERTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; OXYGENATION; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR GROWTH;

EID: 0030498093     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609100716     Document Type: Article

References (35)

1. Adams GE, Ahmed I, Sheldon PW, Stratford IJ. Radiation sensitisation and chemopotentiation: RSU1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 1984; 49: 571-8.
2. Adams GE, Ahmed I, Sheldon PW, Stratford IJ. RSU1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitiser in vitro and in vivo. Int J Radiat Oncol Biol Phys 1984; 10: 1653-6.
3. Stratford IJ, O'Neill P, Sheldon PW, Silver ARJ, Walling JM. Adams GE. RSU1069, a nitroimidazole containing an aziridine group: bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 1986; 35: 105-10.
4. Horwich A, Holliday SB, Deacon JM, Peckham MJ. A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitiser RSU1069. Br J Radiol 1986; 59: 1238-43.
5. Jenkins TC, Naylor MA, O'Neill P, et al. Synthesis and evaluation of α-[[(2-haloethyl)amino]methyl]- 2-nitro-1H-imi-dazole-1-ethanols as prodrugs of α-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1- ethanol (RSU1069) and its analogues which are radiosensitisers and bioreductively activated cytotoxins. J Med Chem 1990; 33: 2603-10.
6. Binger M, Workman P. Pharmacokinetic contribution to the improved therapeutic selectivity of a bromoethylamino pro-drug (RB6145) of the mixed-function hypoxic cell sensitiser/ cytotoxin γ-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU1069). Cancer Chemother Pharmacol 1991; 29: 37-47.
7. Cole S, Stratford, IJ, Adams GE, Fielden EM, Jenkins TC. Dual function 2 nitroimidazoles as hypoxic radiosensitisers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res 1990; 124: 538-43.
8. Cole SA, Stratford IJ, Bowler J, et al. Oral (p.o.) dosing with RSU1069 and RB6145 maintains their potency as hypoxic cell radiosensitisers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice. Int J Radiat Oncol Biol Phys 1991; 21: 387-95.
9. Horsman MR, Chaplin DJ, Overgaard, J. The use of blood flow modifiers to improve the treatment response of solid tumours. Radiother Oncol 1991; (Suppl. 20): 47-2.
10. Chaplin DJ, Peters CE, Horsman MR, Trotter, MJ. Drug induced perturbations in tumour blood flow: therapeutic potential and possible limitations. Radiother Oncol 1991; (Suppl. 20): 93-101.
11. Chaplin DJ, Horsman MR. Tumour blood flow changes induced by chemical modifiers of radiation response. Int J Radiat Oncol Biol Phys 1992; 22: 459-62.
12. Durand RE, LePard NE. Modulation of tumour hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 1994; 29: 481-6.
13. Hirst DG, Brown JM, Hazlehurst, JL. Enhancement of CCNU cytotoxicity by misonidazole: Possible therapeutic gain. Br J Cancer 1982; 46: 109-16.
14. Shepherd AP, Riedel GL, Kiel JW, Haumshild D, Maxwell LC. Evaluation of an infrared laser-Doppler blood flowmeter. Am J Physiol 1987; 252: (Gastrointest. Liver Physiol. 15: G832-839).
15. Shepherd AP, Riedel GL, Kiel JW, Haumshild D, Maxwell LC. Evaluation of an infrared laser-Doppler blood flowmeter. Am J Physiol 1987; 252: (Gastrointest. Liver Physiol. 15: G832-839).
16. 2-histography. Int J Radiat Oncol Biol Phys 1990; 19: 953-61.
17. Tamulevicius P, Luscher G, Streffer C. Effects on intermediary metabolism in mouse tissues by Ro-03-8799. Br J Cancer 1987; 56: 315-20.
18. 3H mammary carcinoma in vivo. Int J Hyperthermia 1989; 5: 123-36.
19. Horsman MR, Christensen KL, Chaplin DJ, Overgaard J. Improved treatment of tumours in vivo by combining the bioreductive drug RSU-1069, hydralazine and hyperthermia. In: Adams GE, Breccia A, Fielden EM, Wardman P, eds. Selective activation of drugs by redox processes. NATO ASI Series. New York: Plenum Press, 1990: 193-202.
20. Vaupel P, Kelleher DK, Engel T. Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour. Br J Cancer 1994; 69: 46-9.
21. Nordsmark M, Grau C, Horsman MR, Stodkilde Jorgensen H, Overgaard J. The relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995; 34: 329-34.
22. Stratford IJ, Walling JM, Silver ARJ. The differential cytotoxicity of RSU1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer 1986; 53: 339-44.
23. 1 mice. Int J Radiat Oncol Biol Phys 1992; 22: 451-4.
24. Stone HB, Minchinton AI, Lemmon M, Menke D, Brown JM. Pharmacological manipulation of tumour blood flow: Lack of correlation between alteration of mean arterial blood pressure and changes in tumour perfusion. Int J Radiat Oncol Biol Phys 1991; 22: 79-86.
25. Streffer C, Zolzer F, Tamulevicius P. Studies on combined treatment with X-rays, hyperthermia and hypoxic cell sensitisers on tumours. In: Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF, eds. Radiation research: A twentieth-century perspective, vol. 2, congress proceedings. San Diego: Academic Press, 1992: 1021-26.
26. Nishimura Y, Hiraoka M, Jo S, et al. Microangiographic and histological analysis of the effects of hyperthermia on murine tumour vasculature. Int J Radiat Oncol Biol Phys 1988; 15: 411-420.
27. Bleehen NM, Honess DJ, Morgan JE. Interaction of hyperthermia and the hypoxic cell sensitiser Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer 1977; 35: 299-306.
28. George KG, Hirst DG, McNally NJ. Effect of hyperthermia on cytotoxicity of the radiosensitiser Ro-07-0582 in a solid mouse tumour. Br J Cancer 1977; 35: 372-5.
29. Lehman CM, Stewart JR. In vivo cytotoxicity of misonidazole and hyperthermia in a transplanted mouse mammary tumour. Radiat Res 1983; 96: 628-34.
30. Stratford IJ. Hyperthermia and hypoxic cell radiosensitisers in combination. In: Anghiteri LJ, Robert J, eds. Hyperthermia and cancer treatment, vol. 1, Florida: CRC Press Inc. 1986; 151-68.
31. Teicher BA, Herman TS, Holden SA. Effect of pH, oxygenation and temperature on the cytotoxicity and radiosensitisation by etanidazole. Int J Radiat Oncol Biol Phys 1991; 20: 723-31.
32. Chaplin DJ, Acker B. The effect of hydralazine on the tumour cytotoxicity of the hypoxic cell cytotoxin RSU-1069: Evidence for therapeutic gain. Int J Radiat Oncol Biol Phys 1987; 13: 579-85.
33. Bremner JCM, Stratford IJ, Bowler J. Adams GE. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 1990; 61: 717-21.
34. Edwards HE, Bremner JCM, Stratford IJ. Induction of tumour hypoxia by FAA and TNF. Int J Radiat Biol 1991; 60: 373-7.
35. G-nitro-L-arginine. Cancer Res 1994; 54: 6458-63.